Business Wire

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future

Share

HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research.

“In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk.

The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scope covers the full range from small synthetic peptides to recombinantly expressed large proteins and will also include chemical modification of the molecules. The ambition is to build a system that is fully integrated with a modern data infrastructure and the data science and machine learning capabilities in Novo Nordisk.

Ira Hoffman, CEO of HighRes Biosolutions, said: “We are very excited to be working with Novo Nordisk on their Lab of the Future. We believe that the combination of our capabilities, products and vision make us the ideal partner for their digital transformation.”

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

About HighRes Biosolutions

HighRes Biosolutions improves human health through life science robotics. The company designs and builds innovative laboratory automation systems, dynamic scheduling software, and lab automation instruments that accelerate and streamline discovery. HighRes offers highly flexible, modular solutions that provide its clients with the ability to scale and reconfigure their automation equipment as their assays or technology changes. Visit www.highresbio.com or follow HighResBio on LinkedIn.

For further information please contact: sales@highresbio.com

Contact information

Media Contact:
HighRes Biosolutions:
Brian O’Sullivan
VP Sales and Marketing
+1 781 932 1912 ext. 1201

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Lancet Simultaneously Publishes Two Phase 3 Studies Detailing Comprehensive Efficacy and Safety of TREMFYA®▼ (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, in Psoriatic Arthritis6.4.2020 15:06:00 EESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that The Lancet has published comprehensive data from DISCOVER-1 and -2, two Phase 3 studies evaluating the safety and efficacy of TREMFYA® (guselkumab) for the treatment of adults with active psoriatic arthritis (PsA).3,4 Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important driver of the pathogenesis of inflammatory diseases such as psoriasis and PsA.5 These are the first publications from a Phase 3 programme reporting safety and efficacy results in active PsA for an antibody with this mechanism of action. Guselkumab is currently not licensed for the treatment of PsA and is undergoing evaluation for this use by the European Medicines Agency (EMA). Data from the two studies in the DISCOVER programme formed the basis of the validated filing on 11 October 2019, to the EMA in the European Union

European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC6.4.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ALUNBRIG (brigatinib) to include use as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on February 27, 2020. “Patients with ALK+ NSCLC, particularly those who have developed brain metastases, have been in need of additional treatment options that are proven effective in the first-line setting,” said Professor Sanjay Popat, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust. “As brigatinib has shown superiority compared to crizotinib in this setting, including in patients whose disease has spread to the brain, this approval is an important advancement for these patients and give

etee X Actronika: launch of a new generation VR haptic controller6.4.2020 15:00:00 EESTPress release

A few months after unveiling their haptic VR vest during the Las Vegas Consumer Electronics Show (CES), Actronika returns to the forefront of the virtual reality scene. The start-up specializing in haptics (the science of touch) is teaming up with TG0, the creator of etee - the first all-finger VR controller for proximity, touch, gesture and pressure sensing. Actronika has integrated their high-definition haptics system into this new generation controller. Imagine being able to touch and feel in the real world what you see in virtual reality! This will be possible starting 2nd April 2020, when the etee controllers reach the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200406005019/en/ Actronika integrates the next generation of haptics into etee - the first full finger control and proximity, touch, gesture and pressure sensing VR controller. On sale from 2nd April 2020. (Photo: TG0) Ready-to-use haptics! etee contr

LFB Announces FDA Approval of SEVENFACT®, a New Recombinant Coagulation Factor VIIa, for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors6.4.2020 14:03:00 EESTPress release

LFB today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) 2061 for SEVENFACT®, a new recombinant coagulation Factor VIIa [coagulation factor VIIa (recombinant)-jncw], for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with Hemophilia A or B with inhibitors (neutralizing antibodies). An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds. Denis Delval LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the FDA approval of SEVENFACT ® which provides a new treatment option for hemophilia patients. This approval is a validation of an innovative LFB technology. We will now work towards SEVENFACT ® registration in Europe and other core countries, in order to offer this therapeutic option to patients.” Hemophilia A or B Hemophilia A or B

Visa Foundation Commits $210 Million to Support Small and Micro Businesses and Immediate COVID-19 Emergency Relief6.4.2020 14:00:00 EESTPress release

The Visa Foundation today announced a commitment of two programs totaling $210 million to support small and micro businesses, aligning with the Foundation’s long-term focus on women’s economic advancement and inclusive economic development, and to address an urgent need from local communities following the spread of COVID-19. The first program of $10 million is designated for immediate emergency relief to support charitable organizations on the frontlines responding to the COVID-19 pandemic, such as public health and food relief, in each of the five geographic regions in which Visa operates: North America; Latin America and the Caribbean; Europe; Asia Pacific; and Central Europe, Middle East and Africa. “As COVID-19 continues to unfold, communities are feeling the effects and need our immediate support,” said Al Kelly, CEO and chairman of Visa. “As a global company that operates a very local business, we recognize this need. We’re also committed to the long-term recovery and will conti

New first-in-class cholesterol-lowering treatment NILEMDO® and its combination with ezetimibe NUSTENDI® approved in Europe6.4.2020 14:00:00 EESTPress release

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that the European Commission (EC) has approved both NILEMDO® (bempedoic acid) and NUSTENDI ® (bempedoic acid / ezetimibe) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia in Europe.4,5 Bempedoic acid has a unique mechanism of action which is complementary to statins and other lipid-lowering therapies (LLTs) allowing additional LDL-C lowering on top of other LLTs compared to placebo.6 Both approvals were supported by data from the CLEAR trial programme conducted in more than 4,000 high- and very high-risk patients.6-10 “Across Europe, cardiovascular disease is one of the major causes of death killing more than four million people every year. High LDL-C is one of the major causes for heart attacks, strokes and other events that can lead to death,” said Professor Alberico L. Catapano, Chairperson of the guidelines Task Force and Professor of Pharmacology at the Department of Pharmacological

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom